Bank of Italy Has $31.72 Million Stock Position in Qiagen N.V. (NYSE:QGEN)

Bank of Italy lowered its stake in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 2.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 799,599 shares of the company's stock after selling 22,846 shares during the quarter. Qiagen comprises 1.7% of Bank of Italy's holdings, making the stock its 8th largest holding. Bank of Italy owned 0.36% of Qiagen worth $31,715,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in QGEN. Brown Brothers Harriman & Co. purchased a new stake in shares of Qiagen during the fourth quarter valued at about $37,000. EverSource Wealth Advisors LLC boosted its stake in Qiagen by 152.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock worth $39,000 after purchasing an additional 526 shares in the last quarter. Smartleaf Asset Management LLC grew its position in Qiagen by 148.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock worth $63,000 after purchasing an additional 835 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Qiagen by 770.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after acquiring an additional 2,204 shares during the period. Finally, GAMMA Investing LLC increased its holdings in shares of Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after purchasing an additional 1,425 shares during the period. Institutional investors own 70.00% of the company's stock.

Wall Street Analyst Weigh In

QGEN has been the topic of several analyst reports. Robert W. Baird increased their price target on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Wall Street Zen raised Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 15th. Finally, Barclays began coverage on shares of Qiagen in a research note on Tuesday. They set an "overweight" rating and a $55.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $48.77.

Qiagen Stock Performance

NYSE QGEN opened at $47.24 on Wednesday. The stock has a fifty day simple moving average of $43.80 and a 200-day simple moving average of $42.44. The company has a current ratio of 3.37, a quick ratio of 2.83 and a debt-to-equity ratio of 0.40. The stock has a market cap of $10.50 billion, a PE ratio of 118.44, a P/E/G ratio of 2.38 and a beta of 0.67. Qiagen N.V. has a twelve month low of $37.63 and a twelve month high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.05. Qiagen had a net margin of 4.68% and a return on equity of 14.61%. The company had revenue of $483.46 million during the quarter, compared to analyst estimates of $465.66 million. During the same quarter last year, the firm posted $0.44 earnings per share. Qiagen's revenue was up 5.2% compared to the same quarter last year. Equities analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.